1
|
Diaz-Gonzalez A, Forner A, Rodriguez de
Lope C and Varela M: New challenges in clinical research on
hepatocellular carcinoma. Rev Esp Enferm Dig. 108:485–493.
2016.PubMed/NCBI
|
2
|
Singal AG, Pillai A and Tiro J: Early
detection, curative treatment, and survival rates for
hepatocellular carcinoma surveillance in patients with cirrhosis: A
metaanalysis. PLoS Med. 11:e10016242014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Mittal S, Kanwal F, Ying J, Chung R, Sada
YH, Temple S, Davila JA and El-Serag HB: Effectiveness of
surveillance for hepatocellular carcinoma in clinical practice: A
United States cohort. J Hepatol. 65:1148–1154. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
5
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Ryan BM, Robles AI and Harris CC: Genetic
variation in microRNA networks: The implications for cancer
research. Nat Rev Cancer. 10:389–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
10
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhang Y, Li T, Qiu Y, Zhang T, Guo P, Ma
X, Wei Q and Han L: Serum microRNA panel for early diagnosis of the
onset of hepatocellular carcinoma. Medicine (Baltimore).
96:e56422017. View Article : Google Scholar : PubMed/NCBI
|
12
|
El-Serag HB, Marrero JA, Rudolph L and
Reddy R: Diagnosis and treatment of hepatocellular carcinoma.
Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ayremlou N, Mozdarani H, Mowla SJ and
Delavari A: Increased levels of serum and tissue miR-107 in human
gastric cancer: Correlation with tumor hypoxia. Cancer Biomark.
15:851–860. 2015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Takahashi Y, Forrest AR, Maeno E,
Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce
cell cycle arrest in human non-small cell lung cancer cell lines.
PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Lee KH, Lotterman C, Karikari C, Omura N,
Feldmann G, Habbe N, Goggins MG, Mendell JT and Maitra A:
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent
kinase 6 expression in pancreatic cancer. Pancreatology. 9:293–301.
2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wang S, Ma G, Zhu H, Lv C, Chu H, Tong N,
Wu D, Qiang F, Gong W, Zhao Q, et al: miR-107 regulates tumor
progression by targeting NF1 in gastric cancer. Sci Rep.
6:365312016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Wang Y, Chen F, Zhao M, Yang Z, Zhang S,
Ye L, Gao H and Zhang X: MiR-107 suppresses proliferation of
hepatoma cells through targeting HMGA2 mRNA 3′UTR. Biochem Biophys
Res Commun. 480:455–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Jiang R, Zhang C, Liu G, Gu R and Wu H:
MicroRNA-107 promotes proliferation, migration, and invasion of
osteosarcoma cells by targeting tropomyosin 1. Oncol Res.
25:1409–1419. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
He J, Zhang W, Zhou Q, Zhao T, Song Y,
Chai L and Li Y: Low-expression of microRNA-107 inhibits cell
apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell
Biol. 45:1962–1973. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yamakuchi M, Lotterman CD, Bao C, Hruban
RH, Karim B, Mendell JT, Huso D and Lowenstein CJ: P53-induced
microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad
Sci USA. 107:6334–6339. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Hollinger S and Hepler JR: Cellular
regulation of RGS proteins: Modulators and integrators of G protein
signaling. Pharmacol Rev. 54:527–559. 2002. View Article : Google Scholar : PubMed/NCBI
|
22
|
Gerber KJ, Squires KE and Hepler JR: Roles
for regulator of G protein signaling proteins in synaptic signaling
and plasticity. Mol Pharmacol. 89:273–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
23
|
Xie Y, Wolff DW, Wei T, Wang B, Deng C,
Kirui JK, Jiang H, Qin J, Abel PW and Tu Y: Breast cancer migration
and invasion depend on proteasome degradation of regulator of
G-protein signaling 4. Cancer Res. 69:5743–5751. 2009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Louwette S, Van Geet C and Freson K:
Regulators of G protein signaling: role in hematopoiesis,
megakaryopoiesis and platelet function. J Thromb Haemost.
10:2215–2222. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Xie Z, Chan EC and Druey KM: R4 regulator
of G protein signaling (RGS) proteins in inflammation and immunity.
AAPS J. 18:294–304. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Siderovski DP and Willard FS: The GAPs,
GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J
Biol Sci. 1:51–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ross EM and Wilkie TM: GTPase-activating
proteins for heterotrimeric G proteins: Regulators of G protein
signaling (RGS) and RGS-like proteins. Annu Rev Biochem.
69:795–827. 2000. View Article : Google Scholar : PubMed/NCBI
|
28
|
Park HJ, Kim SH and Moon DO: Growth
inhibition of human breast carcinoma cells by overexpression of
regulator of G-protein signaling 4. Oncol Lett. 13:4357–4363. 2017.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Bansal G, Druey KM and Xie Z: R4RGS
proteins: Regulation of G-protein signaling and beyond. Pharmacol
Ther. 116:473–495. 2007. View Article : Google Scholar : PubMed/NCBI
|
30
|
Cheng C, Yue W, Li L, Li S, Gao C, Si L
and Tian H: Regulator of G-protein signaling 4: A novel tumor
suppressor with prognostic significance in non-small cell lung
cancer. Biochem Biophys Res Commun. 469:384–391. 2016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Falzone L, Salemi R, Travali S, Scalisi A,
McCubrey JA, Candido S and Libra M: MMP-9 overexpression is
associated with intragenic hypermethylation of MMP9 gene in
melanoma. Aging (Albany NY). 8:933–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
32
|
Marusak C, Bayles I, Ma J, Gooyit M, Gao
M, Chang M and Bedogni B: The thiirane-based selective MT1-MMP/
MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays
metastatic dissemination. Pharmacol Res. 113:515–520. 2016.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Sooro MA, Zhang N and Zhang P: Targeting
EGFR-mediated autophagy as a potential strategy for cancer therapy.
Int J Cancer. 143:2116–2125. 2018. View Article : Google Scholar : PubMed/NCBI
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
36
|
Cai L and Cai X: Up-regulation of miR-9
expression predicate advanced clinicopathological features and poor
prognosis in patients with hepatocellular carcinoma. Diagn Pathol.
9:10002014. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ram Kumar RM, Boro A and Fuchs B:
Involvement and clinical aspects of microRNA in osteosarcoma. Int J
Mol Sci. 17:E8772016. View Article : Google Scholar : PubMed/NCBI
|
38
|
Gao B, Hao S, Tian W, Jiang Y, Zhang S,
Guo L, Zhao J, Zhang G, Yan J and Luo D: MicroRNA-107 is
downregulated and having tumor suppressive effect in breast cancer
by negatively regulating BDNF. J Gene Med. Dec 19–2017.(Epub ahead
of print). doi: 10.1002/jgm.2932. View Article : Google Scholar
|
39
|
Imamura T, Komatsu S, Ichikawa D, Miyamae
M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Konishi H, Shiozaki
A, et al: Depleted tumor suppressor miR-107 in plasma relates to
tumor progression and is a novel therapeutic target in pancreatic
cancer. Sci Rep. 7:57082017. View Article : Google Scholar : PubMed/NCBI
|
40
|
Zhang L, Ma P, Sun LM, Han YC, Li BL, Mi
XY, Wang EH and Song M: MiR-107 down-regulates SIAH1 expression in
human breast cancer cells and silencing of miR-107 inhibits tumor
growth in a nude mouse model of triple-negative breast cancer. Mol
Carcinog. 55:768–777. 2016. View Article : Google Scholar : PubMed/NCBI
|
41
|
Xia H, Li Y and Lv X: MicroRNA-107
inhibits tumor growth and metastasis by targeting the BDNF-mediated
PI3K/AKT pathway in human nonsmall lung cancer. Int J Oncol.
49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
|
42
|
Datta J, Smith A, Lang JC, Islam M, Dutt
D, Teknos TN and Pan Q: microRNA-107 functions as a candidate
tumor-suppressor gene in head and neck squamous cell carcinoma by
downregulation of protein kinase cvarepsilon. Oncogene.
31:4045–4053. 2012. View Article : Google Scholar : PubMed/NCBI
|
43
|
Hao J, Michalek C, Zhang W, Zhu M, Xu X
and Mende U: Reguation of cardiomyocyte signaling by RGS proteins:
Differential selectivity towards G proteins and susceptibility to
regulation. J Mol Cell Cardiol. 41:51–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
44
|
Cao X, Qin J, Xie Y, Khan O, Dowd F,
Scofield M, Lin MF and Tu Y: Regulator of G-protein signaling 2
(RGS2) inhibits androgen-independent activation of androgen
receptor in prostate cancer cells. Oncogene. 25:3719–3734. 2006.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Xu Z, Zuo Y, Wang J, Yu Z, Peng F, Chen Y,
Dong Y, Hu X, Zhou Q, Ma H, et al: Overexpression of the regulator
of G-protein signaling 5 reduces the survival rate and enhances the
radiation response of human lung cancer cells. Oncol Rep.
33:2899–2907. 2015. View Article : Google Scholar : PubMed/NCBI
|
46
|
Liang G, Bansal G, Xie Z and Druey KM:
RGS16 inhibits breast cancer cell growth by mitigating
phosphatidylinositol 3-kinase signaling. J Biol Chem.
284:21719–21727. 2009. View Article : Google Scholar : PubMed/NCBI
|
47
|
James MA, Lu Y, Liu Y, Vikis HG and You M:
RGS17, an overexpressed gene in human lung and prostate cancer,
induces tumor cell proliferation through the cyclic AMP-PKA-CREB
pathway. Cancer Res. 69:2108–2116. 2009. View Article : Google Scholar : PubMed/NCBI
|
48
|
Kelly P, Moeller BJ, Juneja J, Booden MA,
Der CJ, Daaka Y, Dewhirst MW, Fields TA and Casey PJ: The G12
family of heterotrimeric G proteins promotes breast cancer invasion
and metastasis. Proc Natl Acad Sci USA. 103:8173–8178. 2006.
View Article : Google Scholar : PubMed/NCBI
|
49
|
Hu Y, Xing J, Chen L, Zheng Y and Zhou Z:
RGS22 inhibits pancreatic adenocarcinoma cell migration through the
G12/13 α subunit/F-actin pathway. Oncol Rep. 34:2507–2514. 2015.
View Article : Google Scholar : PubMed/NCBI
|
50
|
Tan X, Thapa N, Sun Y and Anderson RA: A
kinase-independent role for EGF receptor in autophagy initiation.
Cell. 160:145–160. 2015. View Article : Google Scholar : PubMed/NCBI
|